Your browser is no longer supported. Please, upgrade your browser.
INNT Innovate Biopharmaceuticals, Inc. daily Stock Chart
Innovate Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own30.80% Shs Outstand1.27M Perf Week1.57%
Market Cap22.94M Forward P/E- EPS next Y- Insider Trans- Shs Float1.11M Perf Month241.40%
Income-6.60M PEG- EPS next Q- Inst Own1.90% Short Float7.86% Perf Quarter193.66%
Sales2.30M P/S9.97 EPS this Y- Inst Trans9.04% Short Ratio0.38 Perf Half Y131.63%
Book/sh-0.35 P/B- EPS next Y- ROA- Target Price- Perf Year33.78%
Cash/sh0.31 P/C57.34 EPS next 5Y- ROE- 52W Range3.43 - 25.80 Perf YTD196.07%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.00% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin0.50% 52W Low426.53% ATR2.75
Employees24 Current Ratio0.30 Sales Q/Q-45.50% Oper. Margin- RSI (14)63.86 Volatility15.75% 29.52%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.60 Prev Close18.21
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume228.59K Price18.06
Recom- SMA2049.50% SMA50127.35% SMA200154.81% Volume134,930 Change-0.82%
Mar-13-18 07:32AM  Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer GlobeNewswire -9.69%
Mar-07-18 07:32AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, 2018, Tuesday at 8:40 AM ET GlobeNewswire -10.34%
Mar-06-18 08:20AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical ACCESSWIRE -16.18%
Feb-13-18 11:19AM  How Does Innovate Biopharmaceuticals Inc (NASDAQ:INNT)s Prospect Stack Up Next To Its Healthcare Peers? Simply Wall St.
Feb-07-18 10:30AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:30PM ET GlobeNewswire -11.04%
Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company's INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.